Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 28, Issue -, Pages 38-42Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2016.02.012
Keywords
-
Categories
Funding
- Amgen
- UCB
- Eli Lilly
- Merck, Sharp Dohme
- Novo Nordisk
- Orkla Health
Ask authors/readers for more resources
Efficient therapies are available for the treatment of osteoporosis, however, there are still unmet needs. Anti-resorptive therapies only increase bone mineral density to a certain extent and reduce the risk of non-vertebral fractures by 20%, only one anabolic option is available the effect of which levels off over time, and the evidence for combination therapy targeting both resorption and formation is limited. The current review will focus on emerging treatments of osteoporosis with the potential of enhanced anabolic effects (romosozumab and abaloparatide) or uncoupling of resorption and formation (odanacatib and romosozumab) as well as the effect of combination therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available